U.S. (state-by-state analysis) Food Allergens and Intolerance Diagnostics Testing Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Food Allergens and Intolerance Diagnostics Testing Market Size

• The U.S. (state-by-state analysis) food allergens and intolerance diagnostics testing market size was valued at USD 1.68 billion in 2024 and is expected to reach USD 3.38 billion by 2032, at a CAGR of 8.90% during the forecast period
• The market growth is largely fueled by rising awareness of food allergies and intolerances, along with increasing prevalence of related conditions across all age groups. Growing demand for early detection, preventive healthcare, and personalized dietary management is driving adoption of Food Allergens and Intolerance Diagnostics Testing solutions
• Furthermore, advancements in diagnostic technologies, such as immunoassays, ELISA-based tests, and point-of-care testing devices, are enhancing accuracy, speed, and ease of use. Expansion of healthcare infrastructure, rising consumer interest in health monitoring, and greater availability of testing kits in clinics, hospitals, and specialized laboratories are further boosting market growth. These converging factors are accelerating the adoption of Food Allergens and Intolerance Diagnostics Testing solutions, significantly strengthening the industry’s growth trajectory

Food Allergens and Intolerance Diagnostics Testing Market Analysis

• Food Allergens and Intolerance Diagnostics Testing are increasingly vital in modern healthcare due to rising awareness of food allergies and intolerances, growing demand for accurate diagnostics, and the need for timely, patient-centric healthcare solutions
• The escalating demand for food allergens and intolerance diagnostics testing is primarily fueled by increasing prevalence of food allergies, government healthcare initiatives, and rising consumer awareness about personalized nutrition and preventive healthcare
• New York dominated the U.S. food allergens and intolerance diagnostics testing market with the largest revenue share of 40.5% in 2024, driven by advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and the presence of major diagnostic laboratories
• Texas is expected to be the fastest-growing state in the U.S. market during the forecast period, with a projected CAGR of 12.3%, supported by rapid expansion of diagnostic labs, increasing patient awareness, and growing adoption of point-of-care and home-based testing solutions
• The blood test segment dominated with a revenue share of 65.3% in 2024, supported by accuracy, reproducibility, and wide adoption in clinical laboratories. Blood tests provide comprehensive allergen profiling and integration into routine diagnostics

Report Scope and Food Allergens and Intolerance Diagnostics Testing Market Segmentation

Food Allergens and Intolerance Diagnostics Testing Market Trends

Enhanced Convenience and Advancements in Diagnostic Solutions

• A significant and accelerating trend in the U.S. food allergens and intolerance diagnostics testing market is the growing adoption of advanced diagnostic technologies that enable rapid, accurate, and patient-centric testing. These developments are enhancing user convenience and improving clinical outcomes across hospitals, clinics, and home care settings
• Manufacturers are increasingly focusing on integrating compact, easy-to-use devices that allow healthcare providers and patients to perform tests efficiently, reducing the turnaround time for results and facilitating timely medical interventions
• Recent innovations include high-sensitivity allergen panels, multiplex testing kits, and point-of-care solutions that provide comprehensive insights into multiple allergens and intolerances in a single test, improving diagnostic accuracy and patient experience
• The expansion of home-based testing options is creating a more accessible and convenient approach for patients, especially for those with mobility limitations or chronic conditions requiring regular monitoring
• Regulatory approvals, enhanced quality standards, and clinical validation of new diagnostic kits are further supporting the adoption of Food Allergens and Intolerance Diagnostics Testing solutions across the U.S., fostering confidence among healthcare providers and consumers
• This trend towards more reliable, rapid, and user-friendly diagnostic solutions is fundamentally reshaping expectations for food allergy and intolerance management, driving market growth and innovation in both clinical and home-based applications

Food Allergens and Intolerance Diagnostics Testing Market Dynamics

Driver

Growing Need Due to Rising Awareness and Advancements in Diagnostics

• The increasing prevalence of food allergies and intolerances among the U.S. population, coupled with the rising awareness of early detection and management, is a significant driver for the heightened demand for Food Allergens and Intolerance Diagnostics Testing solutions
  • For instance, in April 2024, Thermo Fisher Scientific expanded its immunoassay panel for food allergen detection, offering enhanced sensitivity and broader coverage for multiple allergens. Such strategic developments by leading companies are expected to drive industry growth during the forecast period
• As consumers and healthcare providers seek faster, more accurate, and convenient diagnostic options, advanced testing solutions are being developed with features such as multiplex assays, point-of-care compatibility, and rapid result delivery, providing a compelling improvement over conventional laboratory methods
• Furthermore, the growing preference for home-based or clinic-supported testing and integrated healthcare approaches is making Food Allergens and Intolerance Diagnostics Testing increasingly essential, supporting proactive patient management and timely interventions
• The ability to obtain reliable results quickly, combined with easy-to-use testing kits and enhanced accuracy, is boosting adoption across residential, clinical, and hospital settings. Increasing collaborations between diagnostic companies, healthcare providers, and research institutions further support market expansion

Restraint/Challenge

Challenges Related to Cost, Accessibility, and Technical Limitations

• The relatively high cost of advanced food allergens and intolerance diagnostics testing solutions compared to basic methods can be a barrier to adoption, particularly among price-sensitive consumers or smaller healthcare facilities
• Technical limitations, such as the need for trained personnel to administer certain tests or interpret complex results, can also slow the broader uptake of sophisticated diagnostic solutions
• Moreover, ensuring regulatory compliance, standardization, and quality control across various testing kits presents challenges for manufacturers and healthcare providers alike
• While advancements in technology are gradually improving affordability and ease of use, perceived complexity and costs may still limit adoption in some regions or among certain consumer groups
• Inconsistent reimbursement policies and limited insurance coverage for some diagnostic tests can reduce accessibility for patients, discouraging adoption in outpatient or home-based settings
• Supply chain disruptions, raw material shortages, or delays in regulatory approvals can also hinder timely availability of testing kits in the market, particularly for new or advanced allergen panels
• Consumer skepticism regarding the accuracy and reliability of home-based or rapid diagnostic tests may reduce confidence, further slowing market penetration
• Overcoming these challenges through cost-effective product development, wider accessibility, streamlined testing protocols, and enhanced consumer education will be vital for sustained growth in the Food Allergens and Intolerance Diagnostics Testing market

Food Allergens and Intolerance Diagnostics Testing Market Scope

The market is segmented into four notable segments based on food type, diagnosis, disease, sales channel, and distribution channel.

• By Food Type

On the basis of food type, the market is segmented into milk, egg, wheat and soy, tree nuts/seeds, peanuts, seafood, herbs and spices, fruit/vegetables, beverages, and others. The peanuts segment dominated with the largest revenue share of 22.4% in 2024, driven by the high prevalence of peanut allergies across children and adults, increasing awareness of anaphylaxis risk, and proactive testing in schools and clinics. The segment benefits from rapid detection technologies and routine incorporation into clinical diagnostics. Widespread adoption in hospitals, pediatric clinics, and specialty allergy centers further strengthens its position. Technological innovations such as multiplex allergen kits and improved sensitivity also support dominance. Growing government initiatives for allergy prevention and screening programs enhance market share. Continuous research into allergen prevalence ensures sustained demand. Public awareness campaigns and dietary monitoring reinforce its importance. The segment’s established presence in both diagnostic laboratories and point-of-care facilities consolidates revenue leadership.

The tree nuts/seeds segment is expected to witness the fastest CAGR of 14.1% from 2025 to 2032, fueled by growing awareness of nut allergies and higher consumption of tree nuts in modern diets. The adoption of preventive diagnostic measures across urban populations is accelerating growth. Technological advancements in rapid testing and multiplex screening kits support faster, more accurate detection. Increased focus on personalized nutrition and diet-based healthcare is driving demand. Expansion of allergy clinics and pediatric programs contributes to market uptake. Rising awareness of severe allergic reactions encourages proactive testing. Online platforms and telehealth consultations make testing more accessible. Research initiatives on nut-related allergies stimulate further growth. Marketing and awareness campaigns by healthcare providers reinforce the trend, making it the fastest-growing segment.

• By Diagnosis

On the basis of diagnosis, the market is segmented into blood test and skin-prick test. The blood test segment dominated with a revenue share of 65.3% in 2024, supported by accuracy, reproducibility, and wide adoption in clinical laboratories. Blood tests provide comprehensive allergen profiling and integration into routine diagnostics. Hospitals and specialty clinics prioritize this method for reliability. Technological innovations such as high-throughput ELISA and microarray platforms enhance its market position. Consistent demand from pediatric and adult populations ensures steady growth. Regulatory approvals and standardized protocols reinforce dominance. Blood testing is convenient for multi-allergen screening. Long-term contracts with hospital networks contribute to revenue stability. Its established presence in research and diagnostic labs solidifies leadership.

The skin-prick test segment is expected to witness the fastest CAGR of 12.8% from 2025 to 2032, driven by patient preference for immediate results and direct evaluation of hypersensitivity reactions. Adoption in outpatient and specialized allergy clinics is increasing. Rising interest in holistic diagnostics and preventive health supports growth. Healthcare practitioners recommend it alongside blood tests for comprehensive assessment. Expansion of allergy centers facilitates accessibility. Patient-friendly protocols and minimal invasiveness encourage uptake. Telehealth integration for result interpretation boosts convenience. Training programs for clinicians increase adoption. Market penetration across urban states further accelerates the CAGR.

• By Disease

On the basis of disease, the market is segmented into gastritis, skin disease, oral allergy syndrome, irritable bowel syndrome, migraines, hair loss, weight gain, food protein-induced enterocolitis syndrome (FPIES), and others. The oral allergy syndrome segment dominated with the largest revenue share of 28.7% in 2024, owing to high incidence rates in children and adults and routine adoption in allergy centers and hospitals. Integration into preventive health programs strengthens dominance. Technological innovations and rapid testing kits increase efficiency. Multi-allergen testing adoption supports widespread use. Professional networks and centralized diagnostic labs ensure consistent demand. Patient education programs enhance testing rates. School and community screening initiatives boost market share. Long-standing clinical adoption consolidates revenue leadership. Growing awareness campaigns reinforce dominance in the U.S. market.

The FPIES segment is expected to witness the fastest CAGR of 13.6% from 2025 to 2032, fueled by rising awareness of this rare but severe food allergy among healthcare professionals and parents. Specialized testing kits and diagnostic innovations drive adoption. Expansion of pediatric allergy centers supports growth. Increased telehealth consultations improve accessibility. Preventive care initiatives encourage early diagnosis. Research funding and clinical studies enhance awareness. Marketing campaigns highlight early detection benefits. Home-based test kit adoption accelerates uptake. Urban population engagement contributes to rapid CAGR growth.

• By Sales Channel

On the basis of sales channel, the market is segmented into B2B and B2C. The B2B segment dominated with a 60.2% revenue share in 2024, supported by bulk testing orders from hospitals, clinics, laboratories, and educational institutions. Regular procurement cycles provide steady demand. Hospitals integrate testing into routine diagnostics. Specialty clinics contribute to high-volume sales. Centralized lab networks facilitate distribution efficiency. Government and educational programs support bulk adoption. Partnerships with healthcare providers reinforce dominance. Continuous research initiatives ensure consistent B2B uptake. Large-scale contracts consolidate revenue leadership.

The B2C segment is expected to witness the fastest CAGR of 14.3% from 2025 to 2032, driven by increasing popularity of at-home test kits and online ordering platforms. Consumer preference for preventive health and personalized nutrition fuels growth. Telehealth and digital consultations improve accessibility. Rising awareness of diet-related intolerances boosts adoption. Home sample collection kits enhance convenience. Marketing campaigns target urban populations. Subscription-based testing services encourage repeat usage. Ease of use and fast reporting accelerate adoption. Growing consumer interest in proactive healthcare supports CAGR expansion.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. The hospital pharmacy segment dominated with a 58.9% share in 2024, owing to direct availability of allergen and intolerance tests for patients in medical facilities. Hospitals and clinics prioritize integration into routine care. Trained personnel facilitate administration and guidance. High-volume supply ensures consistent availability. Established logistics support reliability. Adoption in specialty allergy centers reinforces dominance. Multi-allergen kit accessibility enhances market share. Centralized hospital networks provide stable demand. Regulatory compliance ensures widespread use.

The online pharmacy segment is expected to witness the fastest CAGR of 15.2% from 2025 to 2032, driven by e-commerce penetration and doorstep delivery convenience. Growing preference for at-home testing fuels adoption. Improved logistics and secure packaging support consumer confidence. Increased awareness and marketing campaigns accelerate uptake. Telehealth integration for result interpretation improves usability. Access to prescription-based tests promotes convenience. Subscription and delivery models enhance repeat usage. Urban population engagement drives expansion. Digital platforms simplify ordering and reporting, contributing to rapid CAGR growth.

Food Allergens and Intolerance Diagnostics Testing Market Regional Analysis

• New York food allergens and intolerance diagnostics testing market captured the largest revenue share in 2024 within North America, driven by rising awareness of food allergies and intolerances, and increasing adoption of preventive healthcare solutions
• Expansion of advanced diagnostic laboratories, point-of-care testing facilities, and home-based testing solutions is fueling market growth. Consumers are increasingly seeking convenient, reliable, and accurate testing services for dietary management. Rising prevalence of food allergies, coupled with growing public interest in personalized nutrition and preventive health, continues to drive strong adoption
• In addition, technological innovations in rapid testing and integration with healthcare systems further enhance the market’s accessibility and efficiency

New York Food Allergens and Intolerance Diagnostics Testing Market

New York food allergens and intolerance diagnostics testing market dominated the U.S. market with the largest revenue share of 40.5% in 2024. The state’s advanced healthcare infrastructure, early adoption of innovative diagnostic technologies, and the presence of leading diagnostic laboratories are key growth drivers. Strong investments in research and development, a well-established laboratory network, and a population highly aware of preventive healthcare measures contribute to California’s market leadership. The demand for accurate, timely testing for allergens and intolerances is further supported by government health programs, private healthcare initiatives, and active collaborations between diagnostic labs and healthcare providers.

Texas Food Allergens and Intolerance Diagnostics Testing Market

Texas food allergens and intolerance diagnostics testing market is expected to be the fastest-growing state in the U.S. market during the forecast period, with a projected CAGR of 12.3%. Rapid expansion of diagnostic labs, increasing consumer awareness, and the adoption of home-based and point-of-care testing solutions are primary growth enablers. The state’s healthcare infrastructure improvements, supportive public health initiatives, and rising focus on dietary safety contribute to robust market potential. Moreover, Texas is witnessing growing interest in preventive health and wellness, with consumers increasingly seeking accessible, reliable testing services to manage food allergies and intolerances effectively.

Food Allergens and Intolerance Diagnostics Testing Market Share

The Food Allergens and Intolerance Diagnostics Testing industry is primarily led by well-established companies, including:

• Bureau Veritas (France)
• Neogen Corporation (U.S.)
• Intertek Group plc (U.K.)
• Mérieux NutriSciences Corporation (U.S.)
• TÜV SÜD (Germany)
• S.G.S. Société Générale de Surveillance SA (Switzerland)
• YorkTest (U.K.)
• US BioTek Laboratories, L.L.C. (U.S.)
• ALLETESS MEDICAL LABORATORY (U.S.)
• Microbac Laboratories, Inc. (U.S.)
• PCAS Labs (U.S.)
• Eurofins U.S.A. (U.S.)

Latest Developments in U.S. (state-by-state analysis) Food Allergens and Intolerance Diagnostics Testing Market

• In March 2024, Gold Standard Diagnostics launched the SENSIStrip Gluten PowerLine Lateral Flow Device, the first of the new allergy PowerLine tests. This product utilizes a sensitive monoclonal antibody-based detection technology to identify gluten residues in swabs, rinse water, and food matrices, enhancing the accuracy and efficiency of gluten testing in food products
• In October 2024, ALK announced the U.S. FDA approval of its new AllerTest allergy skin testing devices and allergen well trays. The AllerTest line includes single prick and multi-head applicators designed to improve the accuracy and comfort of allergy testing, featuring enhanced ergonomics and smaller tine lengths to minimize patient discomfort
• In July 2024, AliveDx received the IVDR CE Mark for its groundbreaking microarray immunoassay in allergy diagnostics. This advancement allows patients to receive results for multiple allergens from a single blood sample, streamlining the diagnostic process and reducing the need for multiple tests and visits
• In August 2024, Amulet, a company specializing in wearable allergy detection technology, raised USD5.8 million in a Series A funding round. The company is developing a wearable device that enables individuals to test for food allergens on the go, aiming to provide real-time allergy detection for consumers and businesses
• In November 2024, Reacta Healthcare announced the successful completion of a £1 million pediatric food allergy diagnostics project, substantially funded by Innovate UK. This project focuses on developing innovative diagnostics for life-threatening food allergies in children, aiming to improve early detection and management of food allergies

SKU-69825